title: [The clinical analysis of paclitaxel at two dose levels plus carboplatin as the first-line treatment in advanced non-small cell lung cancer].
abstract: OBJECTIVE
  The combination of pacilitaxel and carboplatin has become a widely used regimen in first-line therapy of advanced NSCLC. The aim of this study is to compare the efficacy and safety of paclitaxel plus carboplatin at two dose levels in the first-line treatment of advanced NSCLC patients.
  
  
  METHODS
  From Dec 2006 to Jun 2008, 63 patients (ECOG 0-1) with advanced NSCLC were administered with paclitaxel 175 mg/m² (42 patients) plus carboplatin (AUC 5) or paclitaxel 200 mg/m² (21 patients) plus carboplatin (AUC 5), 3-4 weeks/cycle.
  
  
  RESULTS
  The objective response rate of paclitaxel 175 mg/m² group and paclitaxel 200 mg/m² group was 28.57% vs 33.33% (P=0.698); median time to progression were 6.7 months vs 7.0 months (P=0.561); median overall survival time were 18.7 months vs 19.0 months (P=0.255); one and two-year survival rate were 61.9% vs 66.7% (P=0.711) and 31.0% vs 33.3% (P=0.852), respectively. Neutropenia 3/4 grade was 61.9% vs 33.3% in paclitaxel 200 mg/m² group and paclitaxel 175 mg/m² group (P=0.031).
  
  
  CONCLUSIONS
  175 mg/m² dose paclitaxel causes less neutropenia than higher dose paclitaxel. Response rate, survival rate, time to progression and survival time are not statistically significant in two groups.
authors.affiliation: Department of Pulmonary Medicine, Shanghai Chest hospital, Shanghai Jiaotong University, Shanghai, China.
authors.forename: Jialin
authors.initials: J
authors.lastname: Qian
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Hao
authors.initials: H
authors.lastname: Bai
authors.forename: Baohui
authors.initials: B
authors.lastname: Han
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel